Coronavirus Update: South Korean Nod For AZ/Oxford Vaccine, Actemra Progesses In Japan
South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.
You may also be interested in...
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?
While wealthier countries are able to secure plentiful vaccine supplies, a huge effort will be needed to ensure that people in less well off regions of the world get their fair share. The WHO says the AstraZeneca vaccine should be used in the over-65s and in countries with variants of the virus.
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.